Comparison of lipopolysaccharides and soluble CD14 measurement between clinically endotoxaemic and nonendotoxaemic horses

Abstract

Further investigation is warranted to assess the utility of sCD14 measurement as a clinically useful biomarker to identify endotoxaemia in horses.

Multicentre, blinded, randomised clinical trial comparing the use of flunixin meglumine with firocoxib in horses with small intestinal strangulating obstruction

“…As plasma markers of endotoxaemia, the incidence of sCD14 exceeding the established reference range and TNFα exceeding zero were recorded and compared (Table ) . There were no significant differences in TNFα levels between the two groups at any time period (Fig a, P = 0.50) or in the proportion of horses with detectable plasma TNFα in each group (Fig b, P = 0.40).…”

“…Using the difference and variance in plasma sCD14 measurements in clinical SISO cases with or without clinical signs of endotoxaemia (302.6 AE 465.0 [s.d.] ng/mL, an unpublished data set from Fogle et al [7]), a statistical power of 0.8 and an a of 0.05, enrolment of 76 horses (n = 38 in each treatment group) was initially considered. However, during interim analysis, a statistically significant difference in sCD14 measurements was identified following analysis of 56 enrolled horses after 2 years, and the study was concluded.…”

Serial measurements of Paraoxonase-1 (PON-1) activity in horses with experimentally induced endotoxemia

“…interleukin-6 (IL-6), serum amyloid A (SAA), soluble CD14 (sCD14) and procalcitonin (34,35). Measurement of sCD14 provided contrasting results: no signi cant differences in concentration were recorded among time in experimental settings (34), while sCD14 was higher in in spontaneous clinically endotoxemic than nonendotoxemic horses, showing however no correlation with LPS concentration (36). In many studies involving different types of experimentally induced endotoxemia in horses, cytokine expression was rapidly upregulated.…”

Letter to the Editor: Multicentre, blinded, randomised clinical trial comparing the use of flunixin meglumine with firocoxib in horses with small intestinal strangulating obstruction

“…These clinical benefits were not apparent in the results [1]. In fact the only major statistically significant finding was related to a marker considered a 'poor predictor of clinical endotoxaemia' according to a previous study by coauthors [14].…”